<DOC>
	<DOCNO>NCT01789281</DOCNO>
	<brief_summary>Study allow access everolimus patient everolimus treatment Novartis-sponsored study benefit treatment judge investigator</brief_summary>
	<brief_title>Everolimus Roll-over Protocol Patients Who Have Completed Previous Novartis-sponsored Everolimus Study .</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Patient currently enrol Novartissponsored , CD &amp; MA study receive everolimus everolimus plus Sandostatin LAR Depot fulfil requirement parent study Patient currently benefit treatment everolimus , determine guideline parent protocol . Patient permanently discontinue everolimus study treatment parent study . Patient receive everolimus combination unapproved experimental treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoplasms , Carcinoid tumor , Neuroendocrine tumor</keyword>
</DOC>